Clarified strategies in terms of scope and prioritisation between studies

Shortened timelines for selecting higher value drug candidates

Lower risk in early development programs and optimisation of R&D costs

Higher project team autonomy in regulatory preclinical and clinical development

Enhanced chances for a much higher project valorisation